A Study Of MCG In Cardiac Amyloidosis

Recruiting now

Conditions studied: Amyloidosis

In brief

The primary objective of this observational study is to evaluate the utility of magnetocardiography (MCG) in diagnosing and monitoring disease progression in patients with amyloidosis, and to assess its effectiveness in comparison to other modalities, such as ECG.

Key facts

Study ID

NCT07218705

Run by

Mayo Clinic

People needed

500

Starts

2025-12-03

Expected to finish

2027-11-01

Last updated by the study team

2025-12-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years on the date of consent
• Ability for participant to comply with study requirements
• Written informed consent

You may not qualify if…

• Pregnant or breastfeeding
• Having an active atrial fibrillation episode as seen on most current 12-lead ECG
• Active thoracic metal implants (including pacemaker, insertable cardiac monitor, or internal defibrillator).
• External electrical pads or devices (e.g. Pacer pads, ECG electrodes, heart rate patch), that must remain on patient's chest during MCG scan
• Inability to lie down in a supine/inclined position and stay still on the examination bed
• Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.